Adaptive clinical trial designs for phase I cancer studies
From MaRDI portal
Publication:2452091
Recommendations
- scientific article; zbMATH DE number 5032141
- Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping
- Confirmatory clinical trials with an adaptive design
- Improving the flexibility and efficiency of phase II designs for oncology trials
- Adaptation in clinical development plans and adaptive clinical trial designs
Cites work
- A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches
- A Curve‐Free Method for Phase I Clinical Trials
- A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- A Method for Obtaining and Analyzing Sensitivity Data
- A New Dose‐Finding Design for Bivariate Outcomes
- A new look at evaluating MTD designs in cancer research
- A note on the robustness of the continual reassessment method
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
- A Random Walk Rule for Phase I Clinical Trials
- A semiparametric sequential algorithm for estimation of dose-response curve
- A simple technique to evaluate model sensitivity in the continual reassessment method
- A Stochastic Approximation Method
- Adaptive Bayesian compound designs for dose finding studies
- Adaptive designs for dose-finding based on efficacy-toxicity response
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- Approximate policy optimization and adaptive control in regression models
- Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs
- Bayesian decision procedures based on logistic regression models for dose-finding studies
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Bayesian models and decision algorithms for complex early phase clinical trials
- Bayesian optimal designs for phase I clinical trials
- Coherence principles in dose-finding studies
- Consistency of continual reassessment method under model misspecification
- Continual reassessment and related dose-finding designs
- Continual reassessment designs with early termination
- Continual reassessment method for ordered groups
- Continual reassessment method for partial ordering
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Convergence properties of sequential Bayesian \(D\)-optimal designs
- Cumulative cohort design for dose-finding
- Curve-free and model-based continual reassessment method designs
- Derivation of Exact Distributions Following an Up-and-Down Design
- Design and Analysis of Phase I Clinical Trials
- Design efficiency in dose finding studies
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity
- Designs for Single- or Multiple-Agent Phase I Trials
- Dose finding using the biased coin up-and-down design and isotonic regression
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Dose-finding based on feasibility and toxicity in T-cell infusion trials
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Dose-finding designs for HIV studies
- Dose-finding with two agents in phase I oncology trials
- Efficient Sequential Designs With Binary Data
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
- Existence of three solutions to a second-order nonhomogeneous multipoint boundary-value problem
- Group up-and-down designs for dose-finding
- scientific article; zbMATH DE number 524373 (Why is no real title available?)
- scientific article; zbMATH DE number 1361708 (Why is no real title available?)
- scientific article; zbMATH DE number 1361709 (Why is no real title available?)
- scientific article; zbMATH DE number 1361710 (Why is no real title available?)
- scientific article; zbMATH DE number 5224906 (Why is no real title available?)
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
- Incorporating individual and collective ethics into phase I cancer trial designs
- Miscellanea. A stopping rule for the continual reassessment method
- Monitoring late-onset toxicities in phase I trials using predicted risks
- Non-parametric optimal design in dose finding studies
- Number of patients per cohort and sample size considerations using dose escalation with overdose control
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
- Operating characteristics of the standard phase I clinical trial design.
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Optimal design for nonlinear response models
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
- Properties of frequency distributions induced by general up-and-down methods for estimating quantiles
- Randomized group up and down experiments
- Retrospective Analysis of Sequential Dose‐Finding Designs
- Robust EM continual reassessment method in oncology dose finding
- Sequential designs for dose escalation studies in oncology
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Sequential Designs in Bioassay
- Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
- Small-Sample Confidence Sets for the MTD in a Phase I Clinical Trial
- Statistical Methods for Dose‐Finding Experiments
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Stochastic approximation with virtual observations for dose-finding on discrete levels
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- THE DISTRIBUTION OF THE MAXIMUM LIKELIHOOD ESTIMATOR IN UP-AND-DOWN EXPERIMENTS FOR QUANTAL DOSE-RESPONSE DATA
- The treatment versus experimentation dilemma in dose finding studies
- Theoretical study of the continual reassessment method
- Toxicity in sequential dose-response experiments
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Unifying CRM and EWOC designs for phase I cancer clinical trials
- Up-and-down experiments of first and second order
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Übersichtsarbeiten
Cited in
(23)- Adaptation in clinical development plans and adaptive clinical trial designs
- Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling
- On optimal designs for clinical trials: an updated review
- Randomized phase II cancer clinical trials
- Optimal adaptive two-stage designs for phase II cancer clinical trials
- Sequential methods in multi-arm clinical trials
- Adaptive decision making in a lymphocyte infusion trial
- Properties of adaptive clinical trial signature design in the presence of gene and gene-treatment interaction
- Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials
- Adaptive designs for phase II or III clinical trials for patients with cancer in Cuba
- A Bayesian phase I/II trial design for immunotherapy
- Motivating sample sizes in adaptive phase I trials via Bayesian posterior credible intervals
- Improving the flexibility and efficiency of phase II designs for oncology trials
- A new design of the continual reassessment method
- Bayesian adaptive two-stage design for determining person-time in phase II clinical trials with Poisson data
- Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials
- A batch‐effect adjusted Simon's two‐stage design for cancer vaccine clinical studies
- Performance Measures in Dose‐Finding Experiments
- A continual reassessment method without undue risk of toxicity
- The rapid enrollment design for phase I clinical trials
- Bayesian models and decision algorithms for complex early phase clinical trials
This page was built for publication: Adaptive clinical trial designs for phase I cancer studies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2452091)
